Go to the list of all blogs
Anna G's Avatar
published in Blogs
Feb 16, 2022
TickeronGET DAILY SIGNALS
ViacomCBS (VIAC, $35.99) misses Q4 earnings estimates; changes name to Paramount

ViacomCBS (VIAC, $35.99) misses Q4 earnings estimates; changes name to Paramount

ViacomCBS VIAC shares fell Wednesday, after the media giant reported its fourth quarter earnings that fell short of analysts’ expectations. The company also announced its change of name to Paramount.

Viacom’s earnings for the quarter ended December came in at 26 cents per share, well below the Street forecasts.

 Revenues rose +16% from the year-ago quarter to  $8 billion. Streaming revenues were $1.33 billion while cable network revenues climbed +16.3% to $4 billon. Ad revenues were almost flat vs. last year at $2.6 billion.

ViacomCBS’s Paramount+ streaming service added 1 million subscribers in just a week in November following the release of adult drama “Mayor of Kingstown”, family movie “Clifford the Big Red Dog”,  and concert event “Adele: One Night Only.” During the quarter, it added 9.4 million global streaming subscribers, taking its total count to 56 million subscribers.

The group will also officially change its name to Paramount today, with a new ticker symbol PARA to replace the existing VIAC on the Nasdaq.

ViacomCBS expects to have 100 million streaming subscribers by 2024, up from its prior forecast of around 70 million. The company plans to spend more than $6 billion a year on content. The company projects revenues of around $9 billion for 2024, up from a prior estimate of $6 billion

 

 

Related Ticker: SKYD

SKYD's RSI Indicator ascends from oversold territory

The RSI Oscillator for SKYD moved out of oversold territory on October 21, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 36 similar instances when the indicator left oversold territory. In 28 of the 36 cases the stock moved higher. This puts the odds of a move higher at 78%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SKYD as a result. In 53 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for SKYD just turned positive on October 28, 2026. Looking at past instances where SKYD's MACD turned positive, the stock continued to rise in 34 of 46 cases over the following month. The odds of a continued upward trend are 74%.

Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYD advanced for three days, in 206 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

SKYD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

SKYD moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for SKYD crossed bearishly below the 50-day moving average on October 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKYD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.

The Aroon Indicator for SKYD entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. SKYD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.932) is normal, around the industry mean (13.089). SKYD has a moderately high P/E Ratio (325.833) as compared to the industry average of (39.466). Projected Growth (PEG Ratio) (1.158) is also within normal values, averaging (2.376). Dividend Yield (0.020) settles around the average of (0.047) among similar stocks. P/S Ratio (0.260) is also within normal values, averaging (2.932).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.

Notable companies

The most notable companies in this group are Netflix Inc. (NASDAQ:NFLX), Walt Disney Company (The) (NYSE:DIS), Roku (NASDAQ:ROKU), Skydance Corporation (NYSE:SKYD), AMC Entertainment Holdings (NYSE:AMC), iQIYI (NASDAQ:IQ), HUYA (NYSE:HUYA).

Industry description

Movies/entertainment industry include companies that produce and distribute motion pictures, and companies that operate general entertainment facilities like amusement parks and bowling centers. Some companies in this industry also have professional sports franchises. Live Nation Entertainment, Inc., Liberty Media Corp. and Viacom Inc. are some of the biggest companies in this space.

Market Cap

The average market capitalization across the Movies/Entertainment Industry is 16.69B. The market cap for tickers in the group ranges from 293 to 276.44B. NFLX holds the highest valuation in this group at 276.44B. The lowest valued company is BLMZF at 293.

High and low price notable news

The average weekly price growth across all stocks in the Movies/Entertainment Industry was 5%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was -3%. MSGR experienced the highest price growth at 23%, while MPU experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Movies/Entertainment Industry was 59%. For the same stocks of the Industry, the average monthly volume growth was 31% and the average quarterly volume growth was 18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 56
Price Growth Rating: 55
SMR Rating: 83
Profit Risk Rating: 75
Seasonality Score: 6 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a mass media company, which creates and distributes content across a variety of platforms to audiences around the world.

Industry MoviesEntertainment

Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
RBLX shares plunged approximately 24% in premarket trading on Friday, May 1, 2026, falling roughly $13.36 to around $41.90 from the prior close of approximately $55.26. The primary catalyst was a dramatic cut to full-year 2026 bookings guidance, slashed to $7.33B–$7.60B from $8.28B–$8.55B.
SMMT shares fell approximately 20% in premarket trading on Friday, May 1, 2026, dropping from a prior close of approximately $20.83 to around $16.66. The primary catalyst was the HARMONi-3 interim PFS analysis miss, with the Phase III global trial failing to meet expectations for its squamous cohort, undermining the ivonescimab thesis.